JACOBS LEVY EQUITY MANAGEMENT, INC
Position in ANIK — Anika Therapeutics, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in ANIK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,851,591
+$1,972,020 QoQ
Shares Held
265,627
+35.8% QoQ
Ownership
2.00%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 82%
Shared 0%
None 18%
Common Shares in ANIK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $198,176,624 across 13 Drug Manufacturers - Specialty & Generic names. ANIK ranks #9 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
520,269 | $68,540,238 | |
| 2 | LNTH |
Lantheus Holdings, Inc.
|
577,645 | $43,814,373 | |
| 3 | ZTS |
Zoetis Inc.
|
304,877 | $36,039,510 | |
| 4 | IRWD |
Ironwood Pharmaceuticals Inc
|
3,632,477 | $12,749,994 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,004,373 | $9,561,630 | |
| 6 | BIOA |
BioAge Labs, Inc.
|
420,123 | $7,347,951 | |
| 7 | PAHC |
Phibro Animal Health Corp
|
114,018 | $6,306,335 | |
| 8 | PCRX |
Pacira BioSciences, Inc.
|
188,186 | $4,253,003 |
All Filings in ANIK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,851,591 | 265,627 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,879,571 | 195,585 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,032,251 | 109,814 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $1,262,596 | 119,338 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,048,273 | 136,279 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,958,344 | 118,976 | Shares | Sole | 2025-02-14 | |
| 2022-06-30 | $365,981 | 16,397 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||